⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969046 | 0.65 | — | — | |
| SCHEMBL70020 | 0.62 | — | — | |
| SCHEMBL2001276 | 0.62 | — | — | |
| SCHEMBL16427307 | 0.58 | — | — | |
| SCHEMBL424626 | 0.56 | AXL (0.59) | — | |
| SCHEMBL2881001 | 0.56 | ADORA2A (0.57) | — | |
| Hydrazine SCHEMBL5897595 | 0.55 | AXL (0.38) | — | |
| SCHEMBL22116041 | 0.55 | — | — | |
| SCHEMBL5926130 | 0.54 | ADORA2A (0.31) | — | |
| SCHEMBL167008 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | claimed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | claimed |
| US-20230117605-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS, INC. | 2023-04-20 | — | — | US | claimed |
| EP-4146264-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | claimed |
| US-11560376-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | claimed |
| US-6784174-B1 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TNF | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | claimed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1165566-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASE | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | claimed |
| EP-0915093-B1 | AMIDE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2002-11-27 | — | — | EP | claimed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| US-6166016-A | Amide derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2000-12-26 | — | — | US | claimed |
| EP-0915093-A1 | AMIDE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1999-05-12 | — | — | EP | claimed |